Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential

Toronto, Canada – TheNewswire - April 20, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Company ”) (TSX-V:VPT, OTC:VPTDF) ,  is proud to announce that its proprietary VMS+™ 4.0 ( Ventripoint Medical System) technology has been awarded a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies sub‑category. The Edison Awards are widely regarded as one of the most prestigious global recognitions for innovation. Judged by a peer review panel of senior executives, clinicians, engineers, and technology leaders, Gold awards are reserved for innovations that demonstrate not only technical excellence, but clear differentiation, market readiness, and the potential for sustained real‑world impact. For investors, this recognition represents independent validation of Ventripoint's strategic direction and technological leadership.